News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,451 Results
Type
Article (209)
Company Profile (1)
Press Release (1241)
Section
Business (523)
Career Advice (1)
Deals (42)
Drug Delivery (1)
Drug Development (343)
FDA (25)
Job Trends (28)
News (903)
Policy (45)
Tag
Academia (1)
Alliances (84)
Approvals (26)
Artificial intelligence (4)
Best Places to Work (19)
Biosimilars (1)
Biotechnology (1)
Cancer (19)
Career advice (1)
Clinical research (299)
Collaboration (2)
COVID-19 (7)
Data (9)
Denatured (3)
Diagnostics (1)
Drug pricing (1)
Earnings (228)
Events (315)
Executive appointments (1)
FDA (29)
GLP-1 (1)
Government (6)
Guidances (2)
Healthcare (14)
Infectious disease (7)
IPO (17)
Job creations (10)
Job search strategy (1)
Kidney cancer (4)
Layoffs (1)
Legal (6)
Liver cancer (1)
Lung cancer (1)
Medical device (1)
Medtech (1)
Mergers & acquisitions (25)
NextGen: Class of 2025 (5)
Non-profit (2)
Opinion (6)
Pancreatic cancer (1)
Patents (1)
People (217)
Phase I (117)
Phase II (94)
Phase III (150)
Pipeline (5)
Postmarket research (2)
Preclinical (19)
Prostate cancer (3)
Real estate (5)
Regulatory (43)
Research institute (2)
Special edition (1)
Startups (1)
Date
Last 7 days (3)
Last 30 days (4)
Last 365 days (57)
2025 (39)
2024 (66)
2023 (101)
2022 (118)
2021 (118)
2020 (96)
2019 (64)
2018 (70)
2017 (92)
2016 (81)
2015 (68)
2014 (50)
2013 (36)
2012 (53)
2011 (66)
2010 (49)
Location
Africa (4)
Asia (36)
Australia (6)
California (31)
Canada (1)
Connecticut (1)
Europe (176)
Maryland (1)
Massachusetts (1)
New Jersey (1)
New York (1)
Northern California (18)
South America (4)
Southern California (6)
United States (38)
Washington State (1)
Wisconsin (1)
1,451 Results for "exelixis".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’
In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent exclusivity in 2030.
June 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
July 28, 2025
·
20 min read
Pipeline
Exelixis Looks to Next-Gen Cancer Drug as Cabometyx Underwhelms Again
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma and head-and-neck cancer, with several readouts slated for the second half of 2025.
February 19, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
July 14, 2025
·
1 min read
Press Releases
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
July 24, 2025
·
17 min read
Press Releases
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May 2025
May 8, 2025
·
1 min read
Press Releases
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
·
19 min read
Press Releases
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
June 20, 2025
·
17 min read
Press Releases
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
April 29, 2025
·
1 min read
Press Releases
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
June 23, 2025
·
7 min read
1 of 146
Next
